RE:RE:$0.13 EPS??--Did I read that correctly?For the record, I didn't rate those two previous posts. As for as Medicure's financials, I am extremely satisfied. Although revenue had grown significantly, it wasn't translating to the EPS. This is the first quarter with EPS growth, which is monumental for the company.
After listening to the cc, all I can say is that the Apicore deal is not a matter of if, but when. As someone mentioned, the initial acquisition deal was written when Apicore was a far smaller co.
As far as a wishlist, I wish that Freissen would un-earth MC1 again, it did show potential for other indications and there are no acquisition costs...a huge bonus.